Rosacea is a chronic inflammatory dermatosis that mainly affects the cheeks, nose, chin and forehead. Rosacea usually begins between the ages of 30 and 50, but can occur at any age. Population prevalence rates range from < 1 to 22%, but these percentages are likely influenced by differences in study design, methodology, population, geographic location, and cultural and social differences. Rosacea is characterized by recurrent episodes of flushing or transient erythema, persistent erythema, phymatous changes, papules, pustules, and telangiectasia, and the eyes may be involved. Due to the fact that rosacea affects the face, patients with this pathology often have low self-esteem and are prone to anxiety and depression, because this disease has a cosmetic defect. In addition to general skin care, there are several approved treatment options available to address these issues, both topical and systemic. For some functions, intense pulsed light, laser, and surgery are valuable. Recent advances in basic science have highlighted the role of the innate and adaptive immune system, as well as neurovascular dysregulation, underlying the spectrum of clinical manifestations of rosacea. Endogenous and exogenous stimuli can initiate and exacerbate multiple pathways in patients with rosacea. With the updated diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in the treatment of rosacea, including skin care and cosmetic procedures, topical therapy, oral therapy, laser and light therapy, injection therapy, and combination therapy.